Dave Davies

And when they finally released the drug in 2005, how expensive was it?

And when they finally released the drug in 2005, how expensive was it?

And when they finally released the drug in 2005, how expensive was it?

And what did it cost to manufacture a pill?

And what did it cost to manufacture a pill?

And what did it cost to manufacture a pill?

That heavy cost drew criticism, of course, including from some doctors treating multiple myeloma patients. How did the company respond to complaints that this was just too expensive? I mean the typical claim is, look, we spend a lot on researching and developing these drugs. I mean that really wasn't the case here, was it?

That heavy cost drew criticism, of course, including from some doctors treating multiple myeloma patients. How did the company respond to complaints that this was just too expensive? I mean the typical claim is, look, we spend a lot on researching and developing these drugs. I mean that really wasn't the case here, was it?

That heavy cost drew criticism, of course, including from some doctors treating multiple myeloma patients. How did the company respond to complaints that this was just too expensive? I mean the typical claim is, look, we spend a lot on researching and developing these drugs. I mean that really wasn't the case here, was it?

So when Celgene creates Revlimid and it's an effective treatment for this disease, they have to deal with the fact that you don't keep an exclusive patent forever. There are laws that allow generics to eventually come in, provide competition and lower prices. This company was remarkably effective in stalling that. How did they do it?

So when Celgene creates Revlimid and it's an effective treatment for this disease, they have to deal with the fact that you don't keep an exclusive patent forever. There are laws that allow generics to eventually come in, provide competition and lower prices. This company was remarkably effective in stalling that. How did they do it?

So when Celgene creates Revlimid and it's an effective treatment for this disease, they have to deal with the fact that you don't keep an exclusive patent forever. There are laws that allow generics to eventually come in, provide competition and lower prices. This company was remarkably effective in stalling that. How did they do it?

And the FDA and the Federal Trade Commission became aware of this, took some steps, but somehow were ineffective, right? Right.

And the FDA and the Federal Trade Commission became aware of this, took some steps, but somehow were ineffective, right? Right.

And the FDA and the Federal Trade Commission became aware of this, took some steps, but somehow were ineffective, right? Right.

That's right. For a drug that was released in 2005. So that's a long stretch when Celgene kind of had the ability to raise the cost of the drug at its own discretion. What did you discover about the price hikes?

That's right. For a drug that was released in 2005. So that's a long stretch when Celgene kind of had the ability to raise the cost of the drug at its own discretion. What did you discover about the price hikes?

That's right. For a drug that was released in 2005. So that's a long stretch when Celgene kind of had the ability to raise the cost of the drug at its own discretion. What did you discover about the price hikes?

And you found some evidence of objections even within the company, right?

And you found some evidence of objections even within the company, right?